VRTX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this considerati.

I was too cautious previously on Vertex Pharmaceuticals' prospects. Revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter and 10.6% year-on-year to about $3.21 billion in Q2. On July 6, VRTX announced the acquisition of Crinetics Pharmaceuticals for about $10 billion, thereby strengthening its position in the endocrinology drugs market.

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.

Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.

Vertex Pharmaceuticals is executing a pivotal transition year, evolving from a CF-dominated biotech to a multi-franchise growth platform. 2Q26 revenue rose 12% to $3.33 billion, with strong CF performance and early scaling of Casgevy and Journvax supporting raised FY26 guidance to $13.1–$13.2 billion. VRTX is aggressively reinvesting in pipeline and commercial launches, leveraging a $13.6 billion cash position and diversifying with the Crinetics acquisition.

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic ​fibrosis treatments.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance. “Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pilla.

Evaluate the expected performance of Vertex (VRTX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.